Click for best price
Generic Anticancer Injectables Market Size, Share 2022
This report contains market size and forecasts of Generic Anti-cancer Injectables in Global, including the following market information:
Global Generic Anti-cancer Injectables Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Generic Anti-cancer Injectables market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Bevacizuma Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Generic Anti-cancer Injectables include Teva, Viatris, Biocon, Amgen, Sandoz (Novartis), Pfizer, Qilu Pharmaceutical, Jiangsu Hansoh and CTTQ, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Generic Anti-cancer Injectables companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Generic Anti-cancer Injectables Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Generic Anti-cancer Injectables Market Segment Percentages, by Type, 2021 (%)
Bevacizuma
Rituximab
Herceptin
Paclitaxel
Others
Global Generic Anti-cancer Injectables Market, by Channel, 2017-2022, 2023-2028 ($ millions)
Global Generic Anti-cancer Injectables Market Segment Percentages, by Channel, 2021 (%)
Hospital
Retail
Global Generic Anti-cancer Injectables Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Generic Anti-cancer Injectables Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Generic Anti-cancer Injectables revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Generic Anti-cancer Injectables revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Teva
Viatris
Biocon
Amgen
Sandoz (Novartis)
Pfizer
Qilu Pharmaceutical
Jiangsu Hansoh
CTTQ
Jiangsu Hengrui
CSPC
Innovent Biologics
| Report Attributes |
Report Details |
| Report Title |
Generic Anti-cancer Injectables Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
66 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Generic Anti-cancer Injectables Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Channel
1.3 Global Generic Anti-cancer Injectables Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Generic Anti-cancer Injectables Overall Market Size
2.1 Global Generic Anti-cancer Injectables Market Size: 2021 VS 2028
2.2 Global Generic Anti-cancer Injectables Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Generic Anti-cancer Injectables Players in Global Market
3.2 Top Global Generic Anti-cancer Injectables Companies Ranked by Revenue
3.3 Global Generic Anti-cancer Injectables Revenue by Companies
3.4 Top 3 and Top 5 Generic Anti-cancer Injectables Companies in Global Market, by Revenue in 2021
3.5 Global Companies Generic Anti-cancer Injectables Product Type
3.6 Tier 1, Tier 2 and Tier 3 Generic Anti-cancer Injectables Players in Global Market
3.6.1 List of Global Tier 1 Generic Anti-cancer Injectables Companies
3.6.2 List of Global Tier 2 and Tier 3 Generic Anti-cancer Injectables Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Generic Anti-cancer Injectables Market Size Markets, 2021 & 2028
4.1.2 Bevacizuma
4.1.3 Rituximab
4.1.4 Herceptin
4.1.5 Paclitaxel
4.1.6 Others
4.2 By Type - Global Generic Anti-cancer Injectables Revenue & Forecasts
4.2.1 By Type - Global Generic Anti-cancer Injectables Revenue, 2017-2022
4.2.2 By Type - Global Generic Anti-cancer Injectables Revenue, 2023-2028
4.2.3 By Type - Global Generic Anti-cancer Injectables Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Generic Anti-cancer Injectables Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Retail
5.2 By Channel - Global Generic Anti-cancer Injectables Revenue & Forecasts
5.2.1 By Channel - Global Generic Anti-cancer Injectables Revenue, 2017-2022
5.2.2 By Channel - Global Generic Anti-cancer Injectables Revenue, 2023-2028
5.2.3 By Channel - Global Generic Anti-cancer Injectables Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Generic Anti-cancer Injectables Market Size, 2021 & 2028
6.2 By Region - Global Generic Anti-cancer Injectables Revenue & Forecasts
6.2.1 By Region - Global Generic Anti-cancer Injectables Revenue, 2017-2022
6.2.2 By Region - Global Generic Anti-cancer Injectables Revenue, 2023-2028
6.2.3 By Region - Global Generic Anti-cancer Injectables Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Generic Anti-cancer Injectables Revenue, 2017-2028
6.3.2 US Generic Anti-cancer Injectables Market Size, 2017-2028
6.3.3 Canada Generic Anti-cancer Injectables Market Size, 2017-2028
6.3.4 Mexico Generic Anti-cancer Injectables Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Generic Anti-cancer Injectables Revenue, 2017-2028
6.4.2 Germany Generic Anti-cancer Injectables Market Size, 2017-2028
6.4.3 France Generic Anti-cancer Injectables Market Size, 2017-2028
6.4.4 U.K. Generic Anti-cancer Injectables Market Size, 2017-2028
6.4.5 Italy Generic Anti-cancer Injectables Market Size, 2017-2028
6.4.6 Russia Generic Anti-cancer Injectables Market Size, 2017-2028
6.4.7 Nordic Countries Generic Anti-cancer Injectables Market Size, 2017-2028
6.4.8 Benelux Generic Anti-cancer Injectables Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Generic Anti-cancer Injectables Revenue, 2017-2028
6.5.2 China Generic Anti-cancer Injectables Market Size, 2017-2028
6.5.3 Japan Generic Anti-cancer Injectables Market Size, 2017-2028
6.5.4 South Korea Generic Anti-cancer Injectables Market Size, 2017-2028
6.5.5 Southeast Asia Generic Anti-cancer Injectables Market Size, 2017-2028
6.5.6 India Generic Anti-cancer Injectables Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Generic Anti-cancer Injectables Revenue, 2017-2028
6.6.2 Brazil Generic Anti-cancer Injectables Market Size, 2017-2028
6.6.3 Argentina Generic Anti-cancer Injectables Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Generic Anti-cancer Injectables Revenue, 2017-2028
6.7.2 Turkey Generic Anti-cancer Injectables Market Size, 2017-2028
6.7.3 Israel Generic Anti-cancer Injectables Market Size, 2017-2028
6.7.4 Saudi Arabia Generic Anti-cancer Injectables Market Size, 2017-2028
6.7.5 UAE Generic Anti-cancer Injectables Market Size, 2017-2028
7 Players Profiles
7.1 Teva
7.1.1 Teva Corporate Summary
7.1.2 Teva Business Overview
7.1.3 Teva Generic Anti-cancer Injectables Major Product Offerings
7.1.4 Teva Generic Anti-cancer Injectables Revenue in Global Market (2017-2022)
7.1.5 Teva Key News
7.2 Viatris
7.2.1 Viatris Corporate Summary
7.2.2 Viatris Business Overview
7.2.3 Viatris Generic Anti-cancer Injectables Major Product Offerings
7.2.4 Viatris Generic Anti-cancer Injectables Revenue in Global Market (2017-2022)
7.2.5 Viatris Key News
7.3 Biocon
7.3.1 Biocon Corporate Summary
7.3.2 Biocon Business Overview
7.3.3 Biocon Generic Anti-cancer Injectables Major Product Offerings
7.3.4 Biocon Generic Anti-cancer Injectables Revenue in Global Market (2017-2022)
7.3.5 Biocon Key News
7.4 Amgen
7.4.1 Amgen Corporate Summary
7.4.2 Amgen Business Overview
7.4.3 Amgen Generic Anti-cancer Injectables Major Product Offerings
7.4.4 Amgen Generic Anti-cancer Injectables Revenue in Global Market (2017-2022)
7.4.5 Amgen Key News
7.5 Sandoz (Novartis)
7.5.1 Sandoz (Novartis) Corporate Summary
7.5.2 Sandoz (Novartis) Business Overview
7.5.3 Sandoz (Novartis) Generic Anti-cancer Injectables Major Product Offerings
7.5.4 Sandoz (Novartis) Generic Anti-cancer Injectables Revenue in Global Market (2017-2022)
7.5.5 Sandoz (Novartis) Key News
7.6 Pfizer
7.6.1 Pfizer Corporate Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Generic Anti-cancer Injectables Major Product Offerings
7.6.4 Pfizer Generic Anti-cancer Injectables Revenue in Global Market (2017-2022)
7.6.5 Pfizer Key News
7.7 Qilu Pharmaceutical
7.7.1 Qilu Pharmaceutical Corporate Summary
7.7.2 Qilu Pharmaceutical Business Overview
7.7.3 Qilu Pharmaceutical Generic Anti-cancer Injectables Major Product Offerings
7.7.4 Qilu Pharmaceutical Generic Anti-cancer Injectables Revenue in Global Market (2017-2022)
7.7.5 Qilu Pharmaceutical Key News
7.8 Jiangsu Hansoh
7.8.1 Jiangsu Hansoh Corporate Summary
7.8.2 Jiangsu Hansoh Business Overview
7.8.3 Jiangsu Hansoh Generic Anti-cancer Injectables Major Product Offerings
7.8.4 Jiangsu Hansoh Generic Anti-cancer Injectables Revenue in Global Market (2017-2022)
7.8.5 Jiangsu Hansoh Key News
7.9 CTTQ
7.9.1 CTTQ Corporate Summary
7.9.2 CTTQ Business Overview
7.9.3 CTTQ Generic Anti-cancer Injectables Major Product Offerings
7.9.4 CTTQ Generic Anti-cancer Injectables Revenue in Global Market (2017-2022)
7.9.5 CTTQ Key News
7.10 Jiangsu Hengrui
7.10.1 Jiangsu Hengrui Corporate Summary
7.10.2 Jiangsu Hengrui Business Overview
7.10.3 Jiangsu Hengrui Generic Anti-cancer Injectables Major Product Offerings
7.10.4 Jiangsu Hengrui Generic Anti-cancer Injectables Revenue in Global Market (2017-2022)
7.10.5 Jiangsu Hengrui Key News
7.11 CSPC
7.11.1 CSPC Corporate Summary
7.11.2 CSPC Business Overview
7.11.3 CSPC Generic Anti-cancer Injectables Major Product Offerings
7.11.4 CSPC Generic Anti-cancer Injectables Revenue in Global Market (2017-2022)
7.11.5 CSPC Key News
7.12 Innovent Biologics
7.12.1 Innovent Biologics Corporate Summary
7.12.2 Innovent Biologics Business Overview
7.12.3 Innovent Biologics Generic Anti-cancer Injectables Major Product Offerings
7.12.4 Innovent Biologics Generic Anti-cancer Injectables Revenue in Global Market (2017-2022)
7.12.5 Innovent Biologics Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Generic Anti-cancer Injectables Market Opportunities & Trends in Global Market
Table 2. Generic Anti-cancer Injectables Market Drivers in Global Market
Table 3. Generic Anti-cancer Injectables Market Restraints in Global Market
Table 4. Key Players of Generic Anti-cancer Injectables in Global Market
Table 5. Top Generic Anti-cancer Injectables Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Generic Anti-cancer Injectables Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Generic Anti-cancer Injectables Revenue Share by Companies, 2017-2022
Table 8. Global Companies Generic Anti-cancer Injectables Product Type
Table 9. List of Global Tier 1 Generic Anti-cancer Injectables Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Generic Anti-cancer Injectables Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Generic Anti-cancer Injectables Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Generic Anti-cancer Injectables Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Generic Anti-cancer Injectables Revenue in Global (US$, Mn), 2023-2028
Table 14. By Channel ? Global Generic Anti-cancer Injectables Revenue, (US$, Mn), 2021 & 2028
Table 15. By Channel - Generic Anti-cancer Injectables Revenue in Global (US$, Mn), 2017-2022
Table 16. By Channel - Generic Anti-cancer Injectables Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Generic Anti-cancer Injectables Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Generic Anti-cancer Injectables Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Generic Anti-cancer Injectables Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Generic Anti-cancer Injectables Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Generic Anti-cancer Injectables Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Generic Anti-cancer Injectables Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Generic Anti-cancer Injectables Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Generic Anti-cancer Injectables Revenue, (US$, Mn), 2023-2028
Table 30. Teva Corporate Summary
Table 31. Teva Generic Anti-cancer Injectables Product Offerings
Table 32. Teva Generic Anti-cancer Injectables Revenue (US$, Mn), (2017-2022)
Table 33. Viatris Corporate Summary
Table 34. Viatris Generic Anti-cancer Injectables Product Offerings
Table 35. Viatris Generic Anti-cancer Injectables Revenue (US$, Mn), (2017-2022)
Table 36. Biocon Corporate Summary
Table 37. Biocon Generic Anti-cancer Injectables Product Offerings
Table 38. Biocon Generic Anti-cancer Injectables Revenue (US$, Mn), (2017-2022)
Table 39. Amgen Corporate Summary
Table 40. Amgen Generic Anti-cancer Injectables Product Offerings
Table 41. Amgen Generic Anti-cancer Injectables Revenue (US$, Mn), (2017-2022)
Table 42. Sandoz (Novartis) Corporate Summary
Table 43. Sandoz (Novartis) Generic Anti-cancer Injectables Product Offerings
Table 44. Sandoz (Novartis) Generic Anti-cancer Injectables Revenue (US$, Mn), (2017-2022)
Table 45. Pfizer Corporate Summary
Table 46. Pfizer Generic Anti-cancer Injectables Product Offerings
Table 47. Pfizer Generic Anti-cancer Injectables Revenue (US$, Mn), (2017-2022)
Table 48. Qilu Pharmaceutical Corporate Summary
Table 49. Qilu Pharmaceutical Generic Anti-cancer Injectables Product Offerings
Table 50. Qilu Pharmaceutical Generic Anti-cancer Injectables Revenue (US$, Mn), (2017-2022)
Table 51. Jiangsu Hansoh Corporate Summary
Table 52. Jiangsu Hansoh Generic Anti-cancer Injectables Product Offerings
Table 53. Jiangsu Hansoh Generic Anti-cancer Injectables Revenue (US$, Mn), (2017-2022)
Table 54. CTTQ Corporate Summary
Table 55. CTTQ Generic Anti-cancer Injectables Product Offerings
Table 56. CTTQ Generic Anti-cancer Injectables Revenue (US$, Mn), (2017-2022)
Table 57. Jiangsu Hengrui Corporate Summary
Table 58. Jiangsu Hengrui Generic Anti-cancer Injectables Product Offerings
Table 59. Jiangsu Hengrui Generic Anti-cancer Injectables Revenue (US$, Mn), (2017-2022)
Table 60. CSPC Corporate Summary
Table 61. CSPC Generic Anti-cancer Injectables Product Offerings
Table 62. CSPC Generic Anti-cancer Injectables Revenue (US$, Mn), (2017-2022)
Table 63. Innovent Biologics Corporate Summary
Table 64. Innovent Biologics Generic Anti-cancer Injectables Product Offerings
Table 65. Innovent Biologics Generic Anti-cancer Injectables Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Generic Anti-cancer Injectables Segment by Type in 2021
Figure 2. Generic Anti-cancer Injectables Segment by Channel in 2021
Figure 3. Global Generic Anti-cancer Injectables Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Generic Anti-cancer Injectables Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Generic Anti-cancer Injectables Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Generic Anti-cancer Injectables Revenue in 2021
Figure 8. By Type - Global Generic Anti-cancer Injectables Revenue Market Share, 2017-2028
Figure 9. By Channel - Global Generic Anti-cancer Injectables Revenue Market Share, 2017-2028
Figure 10. By Region - Global Generic Anti-cancer Injectables Revenue Market Share, 2017-2028
Figure 11. By Country - North America Generic Anti-cancer Injectables Revenue Market Share, 2017-2028
Figure 12. US Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Generic Anti-cancer Injectables Revenue Market Share, 2017-2028
Figure 16. Germany Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 17. France Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Generic Anti-cancer Injectables Revenue Market Share, 2017-2028
Figure 24. China Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 28. India Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Generic Anti-cancer Injectables Revenue Market Share, 2017-2028
Figure 30. Brazil Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Generic Anti-cancer Injectables Revenue Market Share, 2017-2028
Figure 33. Turkey Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Generic Anti-cancer Injectables Revenue, (US$, Mn), 2017-2028
Figure 37. Teva Generic Anti-cancer Injectables Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Viatris Generic Anti-cancer Injectables Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Biocon Generic Anti-cancer Injectables Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Amgen Generic Anti-cancer Injectables Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Sandoz (Novartis) Generic Anti-cancer Injectables Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Pfizer Generic Anti-cancer Injectables Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Qilu Pharmaceutical Generic Anti-cancer Injectables Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Jiangsu Hansoh Generic Anti-cancer Injectables Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. CTTQ Generic Anti-cancer Injectables Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Jiangsu Hengrui Generic Anti-cancer Injectables Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. CSPC Generic Anti-cancer Injectables Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Innovent Biologics Generic Anti-cancer Injectables Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
